ACET has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACET has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Adicet Bio's average Accounts Payable for the three months ended in Dec. 2024 was $3.67 Mil. Adicet Bio's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil.
The historical rank and industry rank for Adicet Bio's Days Payable or its related term are showing as below:
Adicet Bio's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same
The historical data trend for Adicet Bio's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Days Payable | Get a 7-Day Free Trial | - | - | - | - | - |
Adicet Bio Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Days Payable | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Adicet Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Adicet Bio's Days Payable distribution charts can be found below:
* The bar in red indicates where Adicet Bio's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Adicet Bio's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
Days Payable (A: Dec. 2024 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (A: Dec. 2023 ) | + | Accounts Payable (A: Dec. 2024 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2024 ) | * | Days in Period |
= | ( (2.625 | + | 4.83) | / | 2 ) | / | 0 | * | 365 |
= | 3.7275 | / | 0 | * | 365 | ||||
= | N/A |
Adicet Bio's Days Payable for the quarter that ended in Dec. 2024 is calculated as:
Days Payable (Q: Dec. 2024 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (Q: Sep. 2024 ) | + | Accounts Payable (Q: Dec. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2024 ) | * | Days in Period |
= | ( (2.5 | + | 4.83) | / | 2 ) | / | 0 | * | 365 / 4 |
= | 3.665 | / | 0 | * | 365 / 4 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Adicet Bio's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael Kauffman | director | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carl L Gordon | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Chen Schor | director, officer: See Remarks | PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Katie Peng | director | C/O ADICET BIO, INC., 200 BERKELEY STREET, 19TH FLOOR, BOSTON MA 02116 |
Steve Dubin | director | |
Don Healey | officer: Chief Technology Officer | 2635 TECHNOLOGY FOREST BOULEVARD, THE WOODLANDS TX 77381 |
Blake Aftab | officer: Chief Scientific Officer | C/O ADICET BIO, INC., 200 CLARENDON STREET, FLOOR 6, BOSTON MA 02116 |
Francesco Galimi | officer: Chief Medical Officer | 12930 VIA ESPERIA, DEL MAR CA 92014 |
Aya Jakobovits | director | 3135 HUTTON DRIVE, BEVERLY HILLS CA 90210 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Andrew Sinclair | director | C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065 |
Bastiano Sanna | director | C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210 |
Orbimed Advisors Israel Ii Ltd | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carrie Krehlik | officer: Chief Human Resources Officer | 6015 COLTON BLVD, OAKLAND CA 94611 |
From GuruFocus
By Business Wire • 11-29-2024
By Business Wire • 07-31-2024
By Business Wire • 12-19-2024
By GuruFocus News • 11-13-2024
By Business Wire • 01-08-2025
By Business Wire • 11-18-2024
By Business Wire • 11-16-2024
By Business Wire • 11-05-2024
By Business Wire • 09-30-2024
By Business Wire • 12-31-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.